GlaxoSmithKline Announces Expanded Indication For Hycamtin(R) To Treat Cervical Cancer In Combination Chemotherapy

Fri, 16 Jun 2006 11:00 AM EST

... GlaxoSmithKline (NYSE:GSK) announced today that the U.S. Food and Drug Administration (FDA)approved Hycamtin (topotecan HCl) in combination with cisplatin, for thetreatment of stage IV-B, recurrent, or persistent carcinoma of the cervix,which is not amenable to curative treatment with surgery and/or radiationtherapy. [click link for full article] ...